Polyradiculoneuropathy
Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots.
Subtype terms (4)
More specific conditions that are subtypes of Polyradiculoneuropathy in the MeSH hierarchy.
- Cauda Equina Syndrome
- Guillain-Barre Syndrome
17 drugs (12 approved, 5 experimental)
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
39 drugs (22 approved, 17 experimental)
- Polyradiculopathy
Drugs by status
Phase 3 trials (9)
Phase 2 trials (9)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (16)
- CSL Behring
- Shire
- Octapharma
- Grifols
- Novartis
- Baxalta
- Laboratoire français de Fractionnement et de Biotechnologies
- National Center for Research Resources (NCRR)
- Ohio State University
- University of Vermont
- Mayo Clinic
- Columbia University
- University of Amsterdam
- Mitsubishi Tanabe
- Vita-Salute University of Milano. Italy
- ICON
Organization Involved with Phase 2 Indications (8)
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (1)